Search - Columbia Technology Ventures

Express Licenses

Search

1,843 results

(0.03 seconds)

Exogenous Rac1 analogs to treat acute lung injury

CU23206

This technology uses exogenous Rac1 analogs in their active form to prevent acute lung injury and acute respiratory distress syndrome.

11Actin Acute respiratory distress syndrome Epithelium

Francine Katz Galina Gusarova Jahar Bhattacharya

Columbia University Medical Center (CUMC)

2024-11-26

Gene editing for treatment of retinitis pigmentosa

CU23293

This technology uses CRISPR-Cas9 gene editing to target prolyl hydroxylase (PHD2) to slow the progression of retinitis pigmentosa (RP).

14Adeno-associated virus Cone cell CRISPR

Stephen H. Tsang M.D., Ph.D.

College of Physicians and Surgeons (CUMC

2024-11-26

Orally administered drug with extended-release for obesity treatment

CU23375

This technology is a nanoparticle-based drug that can be administered orally for effective systemic delivery and sustained release of appetite-suppressing hormone lipocalin-2 (LCN2) to treat obesity.

24Anorectic Beta cell Bioavailability

4Jessica DeAngelis Kam Leong Stavroula Kousteni

Biomedical Engineering Herbert and Florence Irving Center for Clinical Research Physiology and Cellular Biophysics

Columbia University Medical Center (CUMC)Fu Foundation School of Engineering and Applied Science (SEAS)

2024-11-26